Intravesical bacillus calmette-guerin treatment improves patient survival in T1G3 bladder tumours

European Urology

Volumn 41, Issue 6, 2002, Pages 635-642

  Patard, Jean Jacques ^a,c   Rodriguez, Alejandro ^a   Leray, Emmanuelle ^b   Rioux Leclercq, Nathalie ^a   Guillé, François ^a   Lobel, Bernard ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

BCG vaccine; Bladder neoplasm; Carcinoma; Immunotherapy; Prognosis; Survival; Transitional cell

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 0036624748     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00173-2     Document Type: Article

References (27)

1. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8.
2. Kiemeney LALM, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne F. Predictability of recurrent and progressive disease in individual patients with superficial bladder cancer. J Urol 1993;150:60-4.
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680-4.
4. American Joint Committee on Urinary Bladder Cancer. In: Flemming D, Coper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin SH, Yarbro JW, editors. AJCC Cancer Staging Manual. Philadelphia (PA): Lippincott Williams & Williams, 1997. p. 241-6.
5. Herr HW, Jakes G, Sheinfeld J. The T1 bladder tumor. Semin Urol 1990;8:254-61.
6. Smith Jr JA, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stage Ta, T1 and TIS). J Urol 1999;162:1697-701.
7. Brake M, Loertzer H, Horsch R, Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with Bacillus Calmette-Guerin. J Urol 2000;163:1697-701.
8. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-48.
9. Bracken RB, McDonald MW, Johnson DE. Cystectomy for superficial bladder cancer. Urology 1981;18:459-63.
10. Pagano F, Bassi P, Galletti TP, Meneghini A, Milani C, Artibani W. Garbeglio A. Results of contemporary radical cystectomy for invasive bladder cancer: A clinical pathological study with an emphasis on the inadecuacy of the tumor, nodes and metastasis classification. J Urol 1991;145:45-50.
11. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF. Radical cystectomy for stages Ta, Tis, and T1 transitional cell carcinoma of the bladder. J Urol 1994;151:31-6.
12. Freeman JA, Ersig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833-9.
13. Stöckle M. Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy - Often too late? Eur Urol 1987;13:361-7.
14. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomised trial of intravesical doxorubicin and immunotherapy with Bacilli Calmette-Guerin for transitionalcell carcinoma of the bladder. New Engl J Med 1991;325:1205-9.
15. Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10-year follow-up. J Urol 1992;147:1020-3.
16. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153:1444-50.
17. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomised South-West Oncology Group study. J Urol 2000;163:1124-9.
18. Jaske G, Loid W, Seeber G, Hofstadter F, Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavourable tumor? J Urol 1987;137:39-43.
19. Heney NM, Ahmed S, Flanigan MJ, et al. for the National Bladder Cancer Collaborative Group A. Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083-6.
20. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of depth of invasion in stage TI bladder carcinoma: A prospective cohort study. J Urol 1997;157:800-4.
21. Zungri E, Martinez L, Da Silva EA, Pesqueira D, de la Fuente Buceta A, Pereiro B. T1 GIII bladder cancer. Management with transurethral resection only. Eur Urol 1999;36:380-4.
22. Rubben H, Allhoff EP, Marquardt H, et al. Registry for urinary tract tumors RWTH Aachen (RUTTAC 1985), 7th Jahresbericht. Verh Dtsch Gesell Urol 1985;36:737-42.
23. Pansadoro V, Emiliozzi P, Defidio L, et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: Long-term results. J Urol 1995;154:2054-8.
24. Hurle R, Losa A, Manzetti A, Lembo A. Intravesical Bacille Calmette-Guerin in stage TI grade 3 bladder cancer therapy: A 7-year follow-up. Urology 1999;54(2):258-63.
25. Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 1996;155:1907-9.
26. Baniel J, Grauss D, Engelstein D, Sella A. Intravesical Bacillus Calmette-Guerin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998;52(5):785-9.
27. Herr HW. Tumour progression and survival in patients with T1G3 bladder tumors: 15-Year outcome. Br J Urol 1997;80:762-5.